Lp(a):一个临床审查
Khalil Anchouche1, Alexis Baass2, George Thanassoulis1
1McGill University Health Centre and Research Institute, Montreal, QC, Canada; McGill University, Montreal, QC, Canada.
Clinical biochemistry
|April 21, 2025
概括
升高的脂蛋白a (Lp[a]) 是心血管疾病的关键遗传风险因素. 新的Lp[a]降低疗法正在晚期试验中,为未来的临床实践提供了希望.
科学领域:
- 心脏病学 心脏病学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 升高的脂蛋白a (Lp[a]) 是患有动脉样硬化心血管疾病和大动脉狭窄的流行,基因决定的危险因素.
- 目前的指导方针建议进行普遍的Lp[a]查,因为它对心血管健康有重大影响.
研究的目的:
- 提供对脂蛋白 (Lp[a]) 生物学,遗传学和临床关联的全面审查.
- 突出新兴的Lp[a]降低疗法及其潜在的未来临床应用.
主要方法:
- 关于LP的文献综述 (a) 生物学,遗传学和临床关联.
- 对Lp[a]降低剂的当前药物开发管道的分析.
- 讨论新疗法在临床实践中的潜在作用.
主要成果:
- Lp (a) 是心血管疾病的重要遗传风险因素,包括动脉样硬化心血管疾病和大动脉狭窄.
- 针对Lp[a) 减少的几种新疗法正在临床试验的后期阶段.
- 这些疗法对未来的心血管风险管理具有前途,与升高的Lp (a) 相关.
结论:
- 对于心血管风险评估,越来越多地建议对Lp (a) 进行普遍查.
- 新兴的Lp (a) 降低疗法在控制这种风险因素方面取得了重大进展.
- 这些新的治疗方法预计将在未来的心血管医学中发挥关键作用.
相关概念视频
Assessment of apical radial pulse
Apical-Radial (A-R) Pulse Assessment
The A-R pulse assessment involves simultaneous evaluation of the apical and radial pulses. When the apical and radial pulse rates vary, this assessment helps identify a pulse deficit.
Pre-Procedural Preparation
The A-R pulse assessment involves simultaneous evaluation of the apical and radial pulses. When the apical and radial pulse rates vary, this assessment helps identify a pulse deficit.
Pre-Procedural Preparation
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Introduction to Language of Pathophysiology ll
This lesson explores key terms that describe how diseases progress, their outcomes, and their distribution in populations.Diagnostic tests identify diseases and monitor treatment. These include blood and urine tests, biopsies, imaging (X-ray, MRI), and detection of infectious agents.Remission is a reduction or disappearance of symptoms.Exacerbation refers to the worsening of symptoms, such as increased wheezing during an asthma attack.A precipitating factor triggers an acute episode, while a...


